As the largest funder of HIV/AIDS programming in the world, PEPFAR has the power and opportunity to move the dial. A large number of AVAC partners and other civil society organizations in Eastern and Southern Africa heard the call for comments and suggestions for the new strategy—and responded here with seven key priorities.
Seven Global Civil Society Priorities for the 2021-2025 President’s Emergency Plan for AIDS Relief (PEPFAR) Strategy
BioPIC Adaptable Product Introduction Framework
This framework is intended to inform stakeholders involved in all stages of product introduction from clinical research to rollout in low- and middle-income countries (LMICs). While the framework focuses on activities to begin in parallel to phase III clinical trials, stakeholders in early product development phases may also want to understand what to expect in terms of downstream product introduction needs. Stakeholders involved in early product development may also consider leveraging some of the activities included to anticipate future needs.
HIV Vaccine Research: Building on the Lessons from COVID
Building on the lessons of COVID, HIV vaccine advocates can mobilize for an HIV vaccine research and access agenda. This two-page document gives suggested messaging.
Breaking the Bottlenecks to COVID-19 Vaccine Access
This graphic identifies the factors contributing to the bottlenecks in the global supply of COVID-19 vaccines.
Research Work Group of the Federal AIDS Policy Partnership’s response to the NIH Request for Information (RFI)
This letter is the Research Work Group of the Federal AIDS Policy Partnership’s response to the NIH Request for Information (RFI) inviting comments and suggestions to advance and strengthen racial equity, diversity and inclusion in the biomedical research workforce and advance health disparities and health equity research.
Advocates’ Guide to Multipurpose Prevention Technologies
A resource to support advocacy for multipurpose prevention technologies (MPTs). The Guide calls out four areas ripe for advocate involvement. It also provides a snapshot on the status of MPT research and development and data on investments—critical information that can support evidence-based advocacy.
Breaking the cycle of transmission: A human-centered approach to increase adoption and sustained use of HIV prevention among high-risk adolescent girls and young women (AGYW) in South Africa
Download findings from Breaking the Cycle of Transmission, a research effort to better understand AGYW decisions and behaviors related to HIV prevention; identify different segments to better tailor outreach; and how to reach each segment more effectively. The project uses user-centered research and human-centered design and piloting.
The HIV Prevention Market Manager (PMM), co-led by AVAC and CHAI and funded by the Bill & Melinda Gates Foundation, leads the research in partnership with behavioral research firm Final Mile, user-centered design firm Upstream Innovation and market research group Ask AfriKa, with the Surgo Foundation providing strategic guidance.
Evaluating, Scaling up and Enhancing Strategies for Supporting PrEP Continuation and Effective Use
In June 2019, the Prevention Product Manager (PMM)—a joint partnership between AVAC and the Clinton Health Access Initiative (CHAI)—and Jhpiego convened a think tank to consider how best to define and measure PrEP continuation. Its recommendations included modifying current PrEP indicators, recognizing that a single definition of correct or effective use might not be possible given fluctuating and variable HIV risk.
A second think tank was held in September 2020 with the theme Evaluating, Enhancing and Scaling up Strategies for Supporting PrEP Continuation and Effective Use. This think tank explored effective and promising strategies for helping people to stay on PrEP, strategies that can be scaled up across populations and locations.
AVAC’s World AIDS Day 2020 Letter to the World
On World AIDS Day 2020, AVAC hones in on three things that are essential advocacy priorities for the present moment and in 2021.
• Program for choice.
• Pay for the healthcare workforce to achieve health equity.
• Pursue just, equitable access for COVID-19 vaccines, therapeutics and community-led prevention.
A Leap Forward For the Dapivirine Vaginal Ring, the Next Steps Are Critical
After decades of research and advocacy, the Dapivirine Vaginal Ring is now one step closer to becoming available as a discreet, woman-initiated HIV prevention option. In July, the European Medicines Agency (EMA) issued a positive opinion for the ring, allowing the next steps in the regulatory process to go forward. Download this podcast to hear five different perspectives on the ring, how it expands HIV prevention options for women, and the most important next steps to bring the ring to women who need it.